Tan WS, Panchal A, Buckley L, Devall AJ, Loubière LS, Pope AM, Billingham LJ & Kelly JD et al. Radiofrequency-induced thermo-chemotherapy effect versus a second course of Bacillus Calmette-Guérin or institutional standard in patients with recurrence of non–muscle-invasive bladder cancer following induction or maintenance Bacillus Calmette-Guérin therapy (HYMN): a phase III, open-label, randomised controlled trial. European Urology, 28 Sep 2018. DOI: 10.1016/j.eururo.2018.09.005
James ND, Pirrie SJ, Pope AM, et al. Clinical outcomes and survival following treatment of metastatic castrate-refractory prostate cancer with docetaxel alone or with strontium-89, zoledronic acid, or both: The trapeze randomized clinical trial. JAMA Oncology. Jan 2016;2(4):493-9. DOI: 10.1001/jamaoncol.2015.5570
James N, Pirrie S, Pope A, Barton D, Andronis L, Goranitis I, et al. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer. Health Technol Assess. July 2016;20(53). DOI: 10.3310/hta20530
Andronis L, Goranitis I, Pirrie S, Pope A, Barton D, Collins S, et al. Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747). BJU International. July 2016. DOI: 10.1111/bju.13549
Wadhwa VK, Wen K, Pirrie S, Pope AM, James ND. The use of serum markers in prediction of survival in the TRAPEZE factorial trial evaluating docetaxel with zoledronic acid, strontium-89 or both in castrate-refractory prostate cancer (CRPC) metastatic to bone. ASCO Annual Meeting; 2013; Chicago, USA. http://meetinglibrary.asco.org/record/86752/abstract; http://meetinglibrary.asco.org/record/86752/poster
James ND, Pirrie SJ, Pope AM, et al. Clinical outcomes and survival following treatment of metastatic castrate-refractoryprostate cancer with docetaxel alone or with strontium-89, zoledronic acid, or both: The TRAPEZE randomized clinical trial. ASCO General Meeting. 8 Jul 2013; Chicago, USA. http://meetinglibrary.asco.org/record/110280/abstract
James ND, Pirrie SJ, Pope AM, et al. Clinical outcomes and survival following treatment of metastatic castrate-refractory prostate cancer with docetaxel alone or with strontium-89, zoledronic acid, or both: The trapeze randomized clinical trial. NCRI Cancer Conference; 3-6 Nov 2013; Liverpool. UK. http://conference.ncri.org.uk/abstracts/2013/abstracts/A73.htm
James ND, Pirrie SJ, Pope AM, et al. Initial feasibility and safety results from a phase II/III clinical trial to evaluate docetaxel therapy in combination with zoledronic acid +/- strontium-89 in hormone-refractory prostate cancer patients. ASCO Genitourinary Cancers Symposium; 2009; Orlando, USA. http://meetinglibrary.asco.org/content/20302-64